Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 11/2005

01-11-2005

18F-Fluorodeoxyglucose Positron Emission Tomography: Useful Technique for Predicting Malignant Potential of Gastrointestinal Stromal Tumors

Authors: Yoichi Kamiyama, MD, Ryuusuke Aihara, MD, PhD, Toshihiro Nakabayashi, MD, PhD, Erito Mochiki, MD, PhD, Takayuki Asao, MD, PhD, Hiroyuki Kuwano, MD, PhD, Nobuo Oriuchi, MD, PhD, Keigo Endo, MD, PhD

Published in: World Journal of Surgery | Issue 11/2005

Login to get access

Abstract

The malignant potential of gastrointestinal stromal tumors (GISTs) is difficult to diagnose before surgery because the diagnoses are based on tumor diameter and mitotic index. The progression of small GISTs is always observed because they do not seem to have malignant potential. 18F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) is a useful technique for assessing tumor activity. The objective of this study was to determine if FDG-PET is useful for predicting the malignant potential of gastric GISTs. Ten patients diagnosed with gastric GISTs participated. FDG-PET was performed on all of them before tumor resection. A whole-body image was initiated 40 minutes after the injection of 275 to 370 MBq FDG. FDG uptake was assessed by a standardized uptake value. All tumors had FDG uptake. There was a significant correlation between the FDG uptake and both the Ki67 index and the mitotic index but not the tumor diameter. The FDG uptake and malignant potential of gastric GISTs had a significant correlation. FDG-PET may be of considerable value for predicting the malignant potential of gastric GISTs before surgery. A gastric GIST with a high FDG uptake should be regarded as having malignant potential.
Literature
1.
Miettinen M. Gastrointestinal stromal tumors: an immunohistochemical study of cellular differentiation. Am J Clin Pathol 1988;89:601–610PubMed
2.
Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutation of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577–580CrossRefPubMed
3.
Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GI-PACT): gastrointestinal stromal tumors show phenotypic characteristics of the intestinal cells of Cajal. Am J Pathol 1998;152:1259–1269PubMed
4.
DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51–58CrossRefPubMed
5.
Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1–12CrossRefPubMed
6.
DeMatteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;5:466–477
7.
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80CrossRefPubMed
8.
Miettinen M, El-Rifai W, Sobin LH, et al. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;35:478–483
9.
Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573–1581CrossRefPubMed
10.
Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21–26CrossRefPubMed
11.
Kole AC, Plukker JT, Nieweg OE, et al. Positron emission tomography for staging oesophageal and gastroesophageal malignancy. Br J Cancer 1998;78:521–527PubMed
12.
Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000;30:150–185PubMed
13.
Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002;94:921–928PubMed
14.
Mochiki E, Kuwano H, Katoh H, et al. Evaluation of 18F-2-deoxy-d-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247–253CrossRefPubMed
15.
Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl. 5):S60–S65PubMed
16.
Inoue T, Oriuchi N, Kunio M, et al. Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 1999;20:849–857PubMed
17.
Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-(fluorine-18)-fluoro-2-deoxy-d-glucose: variations with body weight and a method for correction. Radiology 1993;189:847–850PubMed
18.
Koga H, Sasaki M, Kuwabara Y, et al. An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 2003;17:733–738PubMedCrossRef
19.
Jerusalem G, Hustinx R, Beguin Y, et al. PET scan imaging in oncology. Eur J Cancer 2003;39:1525–1534CrossRefPubMed
20.
Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol 1999;30:1213–1220PubMed
21.
Wang X, Mori I, Tang W, et al. Helpful parameter for malignant potential of gastrointestinal stromal tumors (GIST). Jpn J Clin Oncol 2002;32:347–351CrossRefPubMed
22.
Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumors. Histopathology 1999;34:416–424CrossRefPubMed
23.
Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003;43:118–126CrossRefPubMed
24.
Hasegawa T, Matsuno Y, Shimoda T, et al. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002;33:669–676PubMed
Metadata
Title
18F-Fluorodeoxyglucose Positron Emission Tomography: Useful Technique for Predicting Malignant Potential of Gastrointestinal Stromal Tumors
Authors
Yoichi Kamiyama, MD
Ryuusuke Aihara, MD, PhD
Toshihiro Nakabayashi, MD, PhD
Erito Mochiki, MD, PhD
Takayuki Asao, MD, PhD
Hiroyuki Kuwano, MD, PhD
Nobuo Oriuchi, MD, PhD
Keigo Endo, MD, PhD
Publication date
01-11-2005
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 11/2005
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-005-0045-6

Other articles of this Issue 11/2005

World Journal of Surgery 11/2005 Go to the issue

OriginalPaper

Does Nephrectomy for Trauma Increase the Risk of Renal Failure?

OriginalPaper

The Use of Stereotactic Excisional Biopsy in the Management of Invasive Breast Cancer

Invited Commentary

Invited Commentary

OriginalPaper

Access to Care and Satisfaction in Colorectal Cancer Patients

Invited Commentary

Invited Commentary

OriginalPaper

Intraoperative Monitoring of Intact PTH in Surgery for Renal Hyperparathyroidism as an Indicator of Complete Parathyroid Removal